Showing papers by "Anton Hagenbeek published in 2001"
TL;DR: A new 3-generation family with FPD/AML with a novel CBFA2 mutation is described, which underscores the necessity of performing mutation analysis of the CB FA2 gene before sibling allogeneic transplantation in families with F PD/AMl.
128 citations
TL;DR: Two different methods that introduce third-base degenerate changes at the cryptic splice sites and so prevent splicing are adopted and the HSV-tk protein is unaltered and the sensitivity of the target cells to GCV is preserved.
55 citations
TL;DR: Orally administered, low dose continuous CP is a feasible, effective and well-tolerated regimen in the management of advanced multiple myeloma.
Abstract: Background: Multiple myeloma is an incurable disease and after several lines of chemotherapy, patients enter a phase in which no standard treatment options are available. The poor outlook of these patients requires mild, palliative therapy with low toxicity. Previously used regimens either require frequent hospital attendance, lack efficacy or have significant toxicity.
Methods: In the current study, daily low dose, oral cyclophosphamide (100 mg) and prednisone (10–20 mg; CP) were administered to patients with advanced myeloma. Forty-two patients with progressive disease after melphalan-based and VAD treatment were enrolled.
Results: Objective responses were observed in 29 of 42 (69%) patients. In responding patients, median overall survival and progression-free survival were 22.2 months and 15.0 months, respectively. In non-responders, median OS was 3.5 months only. Side-effects were limited. Cytopenia was the most frequent event (8/29) prompting dose reduction. CP had to be stopped permanently in four patients (two cytopenia, two infections).
Conclusion: Orally administered, low dose continuous CP is a feasible, effective and well-tolerated regimen in the management of advanced multiple myeloma.
43 citations